Table 1.
Demographic characteristics and symptom profiles for Delta and Omicron variant infected study participants, September 10, 2021, to February 14, 2022
| Omicron | ||||
|---|---|---|---|---|
| Delta | All Omicron | BA.1 | BA.2 | |
| (N = 209) | (N = 1730) | (N = 1706) | (N = 24) | |
| Collection date range | Sep 10, 2021–Jan 7, 2022 | Dec 09, 2021–Feb 14, 2022 | Dec 09, 2021–Feb 14, 2022 | Jan 3, 2022–Feb 4, 2022 |
| Age (years), Median [Min, Max] | 20 [18, 66] | 21 [17, 79] | 21 [17, 79] | 21 [18, 32] |
| Sex, N (%) | ||||
| Male | 86 (41.1) | 715 (41.3) | 705 (41.3) | 10 (41.7) |
| Female | 122 (58.4) | 1007 (58.2) | 993 (58.2) | 14 (58.3) |
| Other | — | 1 (0.1) | 1 (0.1) | — |
| Prefer not to say | 1 (0.5) | 7 (0.4) | 7 (0.4) | — |
| Comorbidities (one or more), N (%) | 55 (26.3) | 445 (25.7) | 441 (25.9) | 4 (16.7) |
| Racea, N (%) | ||||
| American Indian or Alaska Native | 2 (1.0) | 10 (0.6) | 9 (0.5) | 1 (4.2) |
| Asian | 37 (17.7) | 598 (34.6) | 580 (34.0) | 18 (75.0) |
| Black | 2 (1.0) | 41 (2.4) | 40 (2.3) | 1 (4.2) |
| Native Hawaiian or other Pacific Islander | — | 4 (0.2) | 4 (0.2) | — |
| White | 145 (69.4) | 806 (46.6) | 803 (47.1) | 3 (12.5) |
| Other | 4 (1.9) | 85 (4.9) | 84 (4.9) | 1 (4.2) |
| Prefer not to say | 5 (2.4) | 48 (2.8) | 48 (2.8) | — |
| Multiple racesb | 14 (6.7) | 138 (8.0) | 138 (8.1) | — |
| Affiliation, N (%) | ||||
| Student | 190 (90.9) | 1520 (87.9) | 1497 (87.7) | 23 (95.8) |
| On-campus resident | 62 (32.6) | 414 (27.2) | 405 (27.1) | 9 (39.1) |
| Fraternity or sorority resident | 60 (31.6) | 205 (13.5) | 205 (13.8) | — |
| Staff | 12 (5.7) | 167 (9.7) | 166 (9.7) | 1 (4.2) |
| Faculty | 5 (2.4) | 37 (2.1) | 37 (2.2) | — |
| Other | 2 (1.0) | 6 (0.3) | 6 (0.4) | — |
| Household densityc, N (%) | ||||
| 1 | 25 (12.0) | 206 (11.9) | 206 (12.1) | — |
| 2 | 62 (29.7) | 519 (30.0) | 508 (29.8) | 11 (45.8) |
| 3 | 21 (10.0) | 299 (17.3) | 295 (17.3) | 4 (16.7) |
| 4 | 24 (11.5) | 226 (13.1) | 219 (12.8) | 7 (29.2) |
| 5 | 6 (2.9) | 69 (4.0) | 69 (4.0) | — |
| 6 or more | 71 (34.0) | 411 (23.8) | 409 (24.0) | 2 (8.3) |
| Mean (SD)d | 3.66 (1.91) | 3.38 (1.75) | 3.39 (1.75) | 3.08 (1.25) |
| Primary series, N (%) | ||||
| Primary series complete | 137 (65.6) | 1147 (66.3) | 1132 (66.4) | 15 (62.5) |
| BNT162b2 | 95 (69.3) | 694 (60.6) | 683 (60.4) | 11 (73.3) |
| mRNA-1273 | 29 (21.2) | 268 (23.4) | 267 (23.6) | 1 (6.7) |
| Ad26.COV2.S | 11 (8.0) | 49 (4.3) | 48 (4.2) | 1 (6.7) |
| ChAdOx1-S | 1 (0.7) | 14 (1.2) | 12 (1.1) | 2 (13.3) |
| Mix and match | 1 (0.7) | 4 (0.3) | 4 (0.4) | — |
| Unknown manufacturer and date | — | 117 (10.2) | 117 (10.3) | — |
| Days since primary series, Mean (SD) | 190 (40.4) | 270 (51.9) | 271 (51.7) | 241 (55.6) |
| Partially complete primary series | 2 (1.0) | 3 (0.2) | 3 (0.2) | — |
| Not vaccinated | 2 (1.0) | 32 (1.8) | 32 (1.9) | — |
| Invalid dates or no information reported | 68 (32.5) | 548 (31.7) | 539 (31.6) | 9 (37.5) |
| Booster dose, N (%) | ||||
| Fully boosted | 3 (1.4) | 337 (19.5) | 333 (19.5) | 4 (16.7) |
| BNT162b2 | 1 (33.3) | 140 (41.5) | 137 (41.1) | 3 (75.0) |
| mRNA-1273 | — | 94 (27.9) | 94 (28.2) | — |
| Ad26.COV2.S | 2 (66.7) | 10 (3.0) | 9 (2.7) | 1 (25.0) |
| Unknown manufacturer | — | 93 (27.6) | 93 (27.9) | — |
| Days since booster dose, Mean (SD) | 194 (60.4) | 58.4 (51.2) | 57.6 (49.3) | 108 (125) |
| Partially boosted | 1 (0.5) | 42 (2.4) | 42 (2.5) | — |
| Not boosted | 98 (46.9) | 752 (43.5) | 744 (43.6) | 8 (33.3) |
| Invalid dates or no information reported | 107 (51.2) | 599 (34.6) | 587 (34.4) | 12 (50.0) |
| Symptom presence, N (%) | ||||
| Asymptomatic | 38 (18.2) | 316 (18.3) | 312 (18.3) | 4 (16.7) |
| Symptomatic | 171 (81.8) | 1414 (81.7) | 1394 (81.7) | 20 (83.3) |
| COVID-19-like illnesse | 42 (24.6) | 436 (30.8) | 429 (30.8) | 7 (35.0) |
| Influenza-like illnessf | 49 (28.7) | 511 (36.1) | 503 (36.1) | 8 (40.0) |
| Symptom duration (days)g, Mean (SD) | 2.82 (2.03) | 2.76 (1.93) | 2.77 (1.94) | 2.11 (1.05) |
| Number of symptomsh, Mean (SD) | 3.46 (2.37) | 4.17 (2.90) | 4.18 (2.90) | 3.35 (2.60) |
| Runny or stuffy nose | 119 (69.6) | 883 (62.4) | 871 (62.5) | 12 (60.0) |
| Cough | 101 (59.1) | 869 (61.5) | 857 (61.5) | 12 (60.0) |
| Sore throat or itchy/scratchy throat | 96 (56.1) | 979 (69.2) | 966 (69.3) | 13 (65.0) |
| Increased trouble with breathing | 8 (4.7) | 110 (7.8) | 109 (7.8) | 1 (5.0) |
| Muscle or body aches | 27 (15.8) | 422 (29.8) | 420 (30.1) | 2 (10.0) |
| Headache | 68 (39.8) | 667 (47.2) | 662 (47.5) | 5 (25.0) |
| Feeling feverish | 43 (25.1) | 482 (34.1) | 476 (34.1) | 6 (30.0) |
| Feeling more tired than usual | 44 (25.7) | 490 (34.7) | 484 (34.7) | 6 (30.0) |
| Chills or shivering | 27 (15.8) | 345 (24.4) | 339 (24.3) | 6 (30.0) |
| Sweats | 21 (12.3) | 242 (17.1) | 239 (17.1) | 3 (15.0) |
| Rash | 1 (0.6) | 15 (1.1) | 15 (1.1) | — |
| New loss of taste or smell | 19 (11.1) | 39 (2.8) | 39 (2.8) | — |
| Nausea or vomiting | 6 (3.5) | 143 (10.1) | 143 (10.3) | — |
| Ear pain or ear discharge | 6 (3.5) | 63 (4.5) | 62 (4.4) | 1 (5.0) |
| Eye pain | 2 (1.2) | 76 (5.4) | 76 (5.5) | — |
| Diarrhea | 3 (1.8) | 71 (5.0) | 71 (5.1) | — |
aRace is divided into mutually exclusive groups.
bMultiple races included participants reporting more than one of these groups.
cHousehold density was defined as the number of people sharing the same kitchen or living space.
dA household density of 6 was assumed for participants who reported more than 6 household members.
eCOVID-19-like illness (CLI) was defined as self-reported fever, chills, and/or shivering, with cough and/or shortness of breath.
fInfluenza-like illness (ILI) was defined as self-reported fever, chills, and/or shivering, with cough and/or sore throat.
gDuration between symptom onset and first SARS-CoV-2-positive result in symptomatic participants.
hUnique symptoms reported by a participant within 7 days before and after collecting their first SARS-CoV-2-positive swab.